Q-omics provides the consensus-scored RPS8 profile across patient tissues and cancer cell-line models. RPS8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS8 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RPS8 protein abundance shows 28,264 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where RPS8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS8 survival associations across molecular data types. RPS8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS8 RNA expression–survival associations across cancer types. High RPS8 expression shows unfavorable associations in ACC, KIRP, LIHC, SARC and KICH, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS8 RNA expression.
This table summarizes RPS8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPS8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS8 shows lower tumor expression in UCEC and higher tumor expression in KIRC, KIRP, LIHC, THCA and COAD. The KIRC box plot shows higher RPS8 RNA expression in tumor versus normal tissue (log2 FC = +1.097, t-test p < 0.001).
This table shows molecular features associated with RPS8 in patient tissues and cancer cell lines. In patient samples, RPS8 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
